Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML
It is unknown, why only a minority of chronic myeloid leukemia (CML) patients sustains treatment free remission (TFR) after discontinuation of tyrosine kinase inhibitor (TKI) therapy in deep molecular remission (MR). Here we studied, whether expression of the T-cell inhibitory receptor (CTLA-4)-liga...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
27 January 2017
|
| In: |
Leukemia
Year: 2017, Jahrgang: 31, Heft: 4, Pages: 829-836 |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/leu.2017.9 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1038/leu.2017.9 Verlag, Volltext: https://www.nature.com/articles/leu20179 
|
| Verfasserangaben: | C. Schütz, S. Inselmann, S. Sausslele, C.T. Dietz, M.C. Müller, E. Eigendorff, C.A. Brendel, S.K. Metzelder, T.H. Brümmendorf, C. Waller, J. Dengler, M.E. Goebeler, R. Herbst, G. Freunek, S. Hanzel, T. Illmer, Y. Wang, T. Lange, F. Finkernagel, R. Hehlmann, M. Huber, A. Neubauer, A. Hochhaus, J. Guilhot, F. Xavier Mahon, M. Pfirrmann and A. Burchert |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1572139943 | ||
| 003 | DE-627 | ||
| 005 | 20230426124247.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180418s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/leu.2017.9 |2 doi | |
| 035 | |a (DE-627)1572139943 | ||
| 035 | |a (DE-576)502139943 | ||
| 035 | |a (DE-599)BSZ502139943 | ||
| 035 | |a (OCoLC)1341007288 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schütz, Christian |e VerfasserIn |0 (DE-588)1156357098 |0 (DE-627)101914744X |0 (DE-576)502138971 |4 aut | |
| 245 | 1 | 0 | |a Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML |c C. Schütz, S. Inselmann, S. Sausslele, C.T. Dietz, M.C. Müller, E. Eigendorff, C.A. Brendel, S.K. Metzelder, T.H. Brümmendorf, C. Waller, J. Dengler, M.E. Goebeler, R. Herbst, G. Freunek, S. Hanzel, T. Illmer, Y. Wang, T. Lange, F. Finkernagel, R. Hehlmann, M. Huber, A. Neubauer, A. Hochhaus, J. Guilhot, F. Xavier Mahon, M. Pfirrmann and A. Burchert |
| 264 | 1 | |c 27 January 2017 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 18.04.2018 | ||
| 520 | |a It is unknown, why only a minority of chronic myeloid leukemia (CML) patients sustains treatment free remission (TFR) after discontinuation of tyrosine kinase inhibitor (TKI) therapy in deep molecular remission (MR). Here we studied, whether expression of the T-cell inhibitory receptor (CTLA-4)-ligand CD86 (B7.2) on plasmacytoid dendritic cells (pDC) affects relapse risk after TKI cessation. CML patients in MR displayed significantly higher CD86+pDC frequencies than normal donors (P<0.0024), whereas TFR patients had consistently low CD86+pDC (n=12). This suggested that low CD86+pDC might be predictive of TFR. Indeed, in a prospective analysis of 122 patients discontinuing their TKI within the EURO-SKI trial, the one-year relapse-free survival (RFS) was 30.1% (95% CI 15.6-47.9) for patients with >95 CD86+pDC per 105 lymphocytes, but 70.0% (95% CI 59.3-78.3) for patients with <95 CD86+pDC (hazard ratio (HR) 3.4, 95%-CI: 1.9-6.0; P<0.0001). Moreover, only patients with <95 CD86+pDC derived a significant benefit from longer (>8 years) TKI exposure before discontinuation (HR 0.3, 95% CI 0.1-0.8; P=0.0263). High CD86+pDC counts significantly correlated with leukemia-specific CD8+ T-cell exhaustion (Spearman correlation: 0.74, 95%-CI: 0.21-0.92; P=0.0098). Our data demonstrate that CML patients with high CD86+pDC counts have a higher risk of relapse after TKI discontinuation. | ||
| 700 | 1 | |a Saußele, Susanne |d 1968- |e VerfasserIn |0 (DE-588)115839860 |0 (DE-627)69162786X |0 (DE-576)29010694X |4 aut | |
| 700 | 1 | |a Dietz, Christian |d 1980- |e VerfasserIn |0 (DE-588)1011266946 |0 (DE-627)658453009 |0 (DE-576)341229164 |4 aut | |
| 700 | 1 | |a Müller, Martin Christian |d 1972- |e VerfasserIn |0 (DE-588)121360296 |0 (DE-627)705409236 |0 (DE-576)181482819 |4 aut | |
| 700 | 1 | |a Hehlmann, Rüdiger |d 1941- |e VerfasserIn |0 (DE-588)1037003489 |0 (DE-627)751737879 |0 (DE-576)390939463 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia |d London : Springer Nature, 1997 |g 31(2017), 4, Seite 829-836 |h Online-Ressource |w (DE-627)32046699X |w (DE-600)2008023-2 |w (DE-576)094139733 |x 1476-5551 |7 nnas |a Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML |
| 773 | 1 | 8 | |g volume:31 |g year:2017 |g number:4 |g pages:829-836 |g extent:8 |a Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/leu.2017.9 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/leu20179 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180418 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 1037003489 |a Hehlmann, Rüdiger |m 1037003489:Hehlmann, Rüdiger |d 60000 |e 60000PH1037003489 |k 0/60000/ |p 20 | ||
| 998 | |g 121360296 |a Müller, Martin Christian |m 121360296:Müller, Martin Christian |d 60000 |d 61200 |e 60000PM121360296 |e 61200PM121360296 |k 0/60000/ |k 1/60000/61200/ |p 5 | ||
| 998 | |g 1011266946 |a Dietz, Christian |m 1011266946:Dietz, Christian |d 60000 |d 61200 |e 60000PD1011266946 |e 61200PD1011266946 |k 0/60000/ |k 1/60000/61200/ |p 4 | ||
| 998 | |g 115839860 |a Saußele, Susanne |m 115839860:Saußele, Susanne |d 60000 |d 61200 |e 60000PS115839860 |e 61200PS115839860 |k 0/60000/ |k 1/60000/61200/ |p 3 | ||
| 999 | |a KXP-PPN1572139943 |e 3006386760 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"note":["Gesehen am 15.03.04"],"part":{"text":"31(2017), 4, Seite 829-836","volume":"31","pages":"829-836","year":"2017","issue":"4","extent":"8"},"id":{"issn":["1476-5551"],"zdb":["2008023-2"],"eki":["32046699X"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Leukemia","subtitle":"normal and malignant hemopoiesis ; a peer-reviewed journal","title":"Leukemia"}],"origin":[{"dateIssuedKey":"1997","publisherPlace":"London ; Basingstoke [u.a.] ; Basingstoke","publisher":"Springer Nature ; Stockton Press ; Nature Publ. Group","dateIssuedDisp":"1997-"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["Nachgewiesen 11.1997 -"],"language":["eng"],"recId":"32046699X","disp":"Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CMLLeukemia"}],"note":["Gesehen am 18.04.2018"],"physDesc":[{"extent":"8 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"doi":["10.1038/leu.2017.9"],"eki":["1572139943"]},"language":["eng"],"title":[{"title":"Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML","title_sort":"Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML"}],"person":[{"display":"Schütz, Christian","given":"Christian","family":"Schütz","role":"aut"},{"family":"Saußele","given":"Susanne","display":"Saußele, Susanne","role":"aut"},{"display":"Dietz, Christian","given":"Christian","family":"Dietz","role":"aut"},{"role":"aut","family":"Müller","display":"Müller, Martin Christian","given":"Martin Christian"},{"role":"aut","family":"Hehlmann","given":"Rüdiger","display":"Hehlmann, Rüdiger"}],"recId":"1572139943","name":{"displayForm":["C. Schütz, S. Inselmann, S. Sausslele, C.T. Dietz, M.C. Müller, E. Eigendorff, C.A. Brendel, S.K. Metzelder, T.H. Brümmendorf, C. Waller, J. Dengler, M.E. Goebeler, R. Herbst, G. Freunek, S. Hanzel, T. Illmer, Y. Wang, T. Lange, F. Finkernagel, R. Hehlmann, M. Huber, A. Neubauer, A. Hochhaus, J. Guilhot, F. Xavier Mahon, M. Pfirrmann and A. Burchert"]},"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"27 January 2017"}]} | ||
| SRT | |a SCHUETZCHREXPRESSION2720 | ||